107
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Down-Regulation of Activating Transcription Factor 3 (ATF3) in Hepatoblastoma and Its Relationship with Ferroptosis

, , , ORCID Icon, , , , , , , & ORCID Icon show all
Pages 9401-9418 | Published online: 06 Dec 2021

References

  • Bharti S, Bharti J, Sinha A, Yadav T. Common and rare histological variants of hepatoblastoma in children: a pathological diagnosis and review of the literature. Gastrointest Tumors. 2021;8(2):41–46. doi:10.1159/000512236
  • Musick SR, Rouster AS, Babiker HM. Hepatoblastoma. Treasure Island (FL): StatPearls Publishing; 2021.
  • Gao Y, Sun Q, Li H, Xie Y, Yao H, Zhao W. [Therapeutic effect and clinical cost of multi-disciplinary team model of hepatoblastoma in children]. Beijing Da Xue Xue Bao Yi Xue Ban. 2020;53(1):200–203. Chinese.
  • Zhi T, Zhang W, Zhang Y, Hu H, Wang Y, Huang D. A new risk-stratification system for hepatoblastoma in children under six years old and the significance for prognosis evaluation-a 14-year retrospective study from a single center. BMC Cancer. 2021;21(1):397. doi:10.1186/s12885-021-08095-x
  • Venkatramani R, Wang L, Malvar J, et al. Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer. 2012;59(3):493–498. doi:10.1002/pbc.24038
  • Koh K, Namgoong J, Yoon H, et al. Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma. Cancer Med. 2021;10(10):3261–3273. doi:10.1002/cam4.3897
  • Katzenstein H, Furman W, Malogolowkin M, et al. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group AHEP0731 study committee. Cancer. 2017;123(12):2360–2367. doi:10.1002/cncr.30591
  • Schmidt A, Armento A, Bussolati O, et al. Hepatoblastoma: glutamine depletion hinders cell viability in the embryonal subtype but high GLUL expression is associated with better overall survival. J Cancer Res Clin Oncol. 2021;147:3169–3181. doi:10.1007/s00432-021-03713-4
  • Hafberg E, Borinstein S, Alexopoulos S. Contemporary management of hepatoblastoma. Curr Opin Organ Transplant. 2019;24(2):113–117. doi:10.1097/MOT.0000000000000618
  • Wu Y, Zeng L, Qiu R, et al. Two-stage laparoscopic resection of giant hepatoblastoma in infants combined with liver partial partition and artery ligation. World J Surg Oncol. 2021;19(1):63. doi:10.1186/s12957-021-02156-y
  • Lee Y, Tan Y, Oon C. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–196. doi:10.1016/j.ejphar.2018.07.034
  • Nagae G, Yamamoto S, Fujita M, et al. Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun. 2021;12(1):5423. doi:10.1038/s41467-021-25430-9
  • Li J, Cao F, Yin H, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. doi:10.1038/s41419-020-2298-2
  • Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md). 2016;63(1):173–184. doi:10.1002/hep.28251
  • Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020;136(6):726–739. doi:10.1182/blood.2019002907
  • Liang J, Wang D, Lin H, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci. 2020;16(13):2430–2441. doi:10.7150/ijbs.45050
  • Lippmann J, Petri K, Fulda S, Liese J. Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma. Transl Oncol. 2020;13(8):100785. doi:10.1016/j.tranon.2020.100785
  • Ku H, Cheng C. Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer. Front Endocrinol (Lausanne). 2020;11:556. doi:10.3389/fendo.2020.00556
  • Wang L, Liu Y, Du T, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27(2):662–675. doi:10.1038/s41418-019-0380-z
  • Fei Z, Lijuan Y, Jing Z, Xi Y, Yuefen P, Shuwen H. Molecular characteristics associated with ferroptosis in hepatocellular carcinoma progression. Hum Cell. 2021;34(1):177–186. doi:10.1007/s13577-020-00431-w
  • Wang Y, Quan F, Cao Q, et al. Quercetin alleviates acute kidney injury by inhibiting ferroptosis. J Adv Res. 2021;28:231–243. doi:10.1016/j.jare.2020.07.007
  • Chen P, Wu J, Xu Y, et al. Zinc transporter ZIP7 is a novel determinant of ferroptosis. Cell Death Dis. 2021;12(2):198. doi:10.1038/s41419-021-03482-5
  • Eleftheriadis T, Pissas G, Golfinopoulos S, Liakopoulos V, Stefanidis I. Role of indoleamine 2,3-dioxygenase in ischemia-reperfusion injury of renal tubular epithelial cells. Mol Med Rep. 2021;23(6). doi:10.3892/mmr.2021.12111
  • Zhao W, Sun M, Li S, Chen Z, Geng D. Transcription factor ATF3 mediates the radioresistance of breast cancer. J Cell Mol Med. 2018;22(10):4664–4675. doi:10.1111/jcmm.13688
  • Du A, Jiang Y, Fan C. NDRG1 downregulates ATF3 and inhibits cisplatin-induced cytotoxicity in lung cancer A549 cells. Int J Med Sci. 2018;15(13):1502–1507. doi:10.7150/ijms.28055
  • Li L, Song S, Fang X, Cao D. Role of ATF3 as a prognostic biomarker and correlation of ATF3 expression with macrophage infiltration in hepatocellular carcinoma. BMC Med Genomics. 2021;14(1):8. doi:10.1186/s12920-020-00852-4
  • Yan L, Gaddis S, Coletta L, et al. ATF3-induced mammary tumors exhibit molecular features of human basal-like breast cancer. Int J Mol Sci. 2021;22(5):2353. doi:10.3390/ijms22052353
  • Li L, Sun R, Jiang G. ATF3 demethylation promotes the transcription of ARL4C, which acts as a tumor suppressor in human breast cancer. Onco Targets Ther. 2020;13:3467–3476. doi:10.2147/OTT.S243632
  • Asakawa Y, Okabe A, Fukuyo M, et al. Epstein-Barr virus-positive gastric cancer involves enhancer activation through activating transcription factor 3. Cancer Sci. 2020;111(5):1818–1828. doi:10.1111/cas.14370
  • Yuan X, Yu L, Li J, et al. ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton. Cancer Res. 2013;73(12):3625–3637. doi:10.1158/0008-5472.CAN-12-3879
  • Kelly A, Trowsdale J. Genetics of antigen processing and presentation. Immunogenetics. 2019;71(3):161–170. doi:10.1007/s00251-018-1082-2
  • Liu H, Kuang X, Zhang Y, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell. 2020;37(3):324–339.e328. doi:10.1016/j.ccell.2020.02.006
  • Yin X, Wolford C, Chang Y, et al. ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci. 2010;123:3558–3565. doi:10.1242/jcs.064915
  • Stockwell B, Jiang X. A physiological function for ferroptosis in tumor suppression by the immune system. Cell Metab. 2019;30(1):14–15. doi:10.1016/j.cmet.2019.06.012
  • Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z. Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma. Front Cell Dev Biol. 2020;8:596679. doi:10.3389/fcell.2020.596679